A Phase 3 interventional study of denosumab and placebo in Osteoporosis, Postmenopausal, sponsored by GlaxoSmithKline. Completed at 11 sites in India. Open to female participants aged 55 Years to 75 Years. Per ClinicalTrials.gov, last updated 2014-02-07.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies testing denosumab in Osteoporosis, Postmenopausal — 1 open to participants now, 3 under way, 2 of them phase 3. Denosumab · Osteoporosis, Postmenopausal.
Among the 31 studies testing denosumab in Osteoporosis, Postmenopausal, this one is the 17th largest by enrollment, is one of 3 that started in 2012, is one of 17 in phase 3, and was the 12th registered.
334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.
Browse Osteoporosis, Postmenopausal studies →1 of the 31 studies testing denosumab in Osteoporosis, Postmenopausal is open now, in 1 country. Recruiting first, the newest first:
Lambda Therapeutic Research Ltd. · Sites in India
Ages 55–90 · Women only
By country, each count listing its studies:
Denosumab: first FDA approval 2010 (PROLIA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 19 Osteoporosis, Postmenopausal studies recruiting now, 8 (42%) set no upper age limit and 7 (37%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.
This study: 55 Years to 75 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 3 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 250 is above the median of 119 across 264 interventional studies indexed under Osteoporosis, Postmenopausal.
Median enrollment 278 across the 31 interventional studies. Of the 27 that completed or were terminated, 20 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 31 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
GlaxoSmithKline has 7 studies filed under Osteoporosis, Postmenopausal — fewer than ten, so there is no comparison to draw.
1 of the studies testing denosumab in Osteoporosis, Postmenopausal that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05010590Massachusetts General HospitalAnabolic Therapy in Postmenopausal Osteoporosis | 2027-10-01 |
Add it to your calendar (.ics) → With an account.
Among the 31 studies testing denosumab in Osteoporosis, Postmenopausal, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if denosumab is effective in increasing bone mineral density at the lumbar spine in Indian postmenopausal women with osteoporosis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
denosumab 60mg subcutaneous injection, single dose at the start of the 6-month double-blind treatment
Drug: denosumab
placebo subcutaneous injection, single dose at the start of the 6-month double-blind treatment
Drug: placebo
60mg subcutaneous injection, single dose
placebo subcutaneous injection, single dose
Mean Percent Change From Baseline in Bone Mineral Density at the Lumbar Spine at Month 6
Bone mineral density (BMD) at the lumbar spine was measured by the dual-energy x-ray absorptiometry (DXA) scanner. The mean percent change from Baseline in BMD was calculated as: (value at Month 6 minus Baseline value) \* 100 / Baseline value. Analysis was performed using an Analysis of Covariance (ANCOVA) model with terms for treatment and baseline BMD at the lumbar spine (as a continuous covariate).
Time frame: Baseline and Month 6
Mean Percent Change From Baseline in BMD at the Total Hip, Femoral Neck, and Trochanter at Month 6
BMD at the total hip, femoral neck, and trochanter was measured by the DXA scanner. The mean percent change from Baseline in BMD was calculated as: (value at Month 6 minus Baseline value) \* 100 / Baseline value. Analysis was performed using an ANCOVA model with terms for treatment and corresponding Baseline BMD (as a continuous covariate).
Time frame: Baseline and Month 6
Median Percent Change From Baseline in Serum Carboxy-terminal Cross-linking Telopeptide of Type I Collagen (s-CTX) and Serum Procollagen Type IN Propeptide (s-PINP) Markers at Months 1, 3, and 6
Blood samples were collected for the measurement of s-CTx and s-PINP, which are used as biomarkers of bone resorption and formation, respectively. The median percent change from Baseline in s-CTX and s-PINP markers at Months 1, 3, and 6 was calculated as: (post-Baseline value minus Baseline value) \* 100 / Baseline value.
Time frame: Baseline; Months 1, 3, and 6
Number of Participants With Any Adverse Event (AE) and Any Serious Adverse Event (SAE)
An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, or is an event of possible drug-induced liver injury with hyperbilirubinaemia. Medical or scientific judgment was to have been exercised in other important medical events. Refer to the general Adverse AE/SAE module for a complete list of AEs and SAEs.
Time frame: From Baseline up to Month 6
Number of Participants With a Change From Baseline in Vital Signs of Potential Clinical Concern at Months 1, 3, and 6
Vital sign values of potential clinical concern were defined as: change in heart rate \>30 beats per minutes (bpm), change in systolic blood pressure (SBP) \>30 millimeters of mercury (mmHg), and change in diastolic blood pressure (DBP) \>20 mmHg. The number of participants with post-Baseline vital sign values of potential clinical concern who did not have values of potential clinical concern at Baseline are summarized. If the change from Baseline is a decrease greater than the threshold, it is categorized as "low." If the change from Baseline is an increase greater than the threshold, it is categorized ad "high."
Time frame: Baseline; Months 1, 3, and 6
Number of Participants With the Indicated Laboratory Parameter Values of Potential Clinical Concern at Month 6
The number of participants with laboratory parameter values of potential clinical concern at Month 6 are summarized. The following are the laboratory values of potential clinical concern: alkaline phosphatase, High: \>375 units/Liter (L); aspartate aminotransferase, High: \>165 units/L; creatinine, High: \>159 micromoles (µmol)/L; glucose, Low: \<3 millimoles (mmol)/L; hematocrit, Low: \<0.325; hemoglobin, Low: \<91grams/L; phosphorus, High: \>1.723 mmol/L; potassium, High: \>6.3 mmol/L; sodium, Low: \<130 mmol/L; total neutrophils, Low: \<0.9 10\^9 cells (GI)/L; blood urea nitrogen (BUN), High: \>21mmol/L; uric acid, High: 654 µmol/L.
Time frame: Month 6
Change From Baseline in Albumin/Globulin Ratio and Blood Urea Nitrogen (BUN)/Creatinine Ratio at Month 6
Blood samples were collected for the measurement of albumin/globulin ratio and BUN/creatinine ratio values. Change from Baseline was calculated as the Month 6 value minus the Baseline value.
Time frame: Baseline and Month 6
Change From Baseline in Albumin, Hemoglobin, Mean Corpuscle Hemoglobin Concentration (Conc.), and Total Protein at Month 6
Blood samples were collected for the measurement of albumin, hemoglobin, mean corpuscle hemoglobin concentration, and total protein values. Change from Baseline was calculated as the Month 6 value minus the Baseline value.
Time frame: Baseline and Month 6
Change From Baseline in Alkaline Phosphatase, Alanine Amino Transferase, Aspartate Amino Transferase, Creatinine Kinase, Gamma Glutamyl Transferase, and Lactate Dehydrogenase at Month 6
Blood samples were collected for the measurement of alkaline phosphatase, alanine amino transferase, aspartate amino transferase, creatinine kinase, gamma glutamyl transferase, and lactate dehydrogenase values. Change from Baseline was calculated as the Month 6 value minus the Baseline value.
Time frame: Baseline and Month 6
Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Segmented Neutrophils, Total Neutrophils, Platelet Count, and White Blood Cell Count Month 6
Blood samples were collected for the measurement of basophil, eosinophil, lymphocyte, monocyte, segmented neutrophil, total neutrophil, platelet count, and white blood cell count values. Change from Baseline was calculated as the Month 6 value minus the Baseline value.
Time frame: Baseline and Month 6
Change From Baseline in Direct Bilirubin, Indirect Bilirubin, Total Bilirubin, Creatinine, and Uric Acid at Month 6
Blood samples were collected for the measurement of direct bilirubin, indirect bilirubin, total bilirubin, creatinine, and uric acid values. Change from Baseline was calculated as the Month 6 value minus the Baseline value.
Time frame: Baseline and Month 6
Change From Baseline in Calcium Corrected, Calcium, Chloride, Glucose, Potassium, Magnesium, Sodium, Phosphorus Inorganic, Triglycerides, Urea/BUN, and Very Low-density Lipoproteins (VLDL) Cholesterol Calculation at Month 6
Blood samples were collected for the measurement of calcium corrected, calcium, chloride, glucose, potassium, magnesium, sodium, phosphorus inorganic, triglyceride, urea/BUN, and VLDL cholesterol calculation values. Change from Baseline was calcualted as the Month 6 value minus the Baseline value.
Time frame: Baseline and Month 6
Change From Baseline in Hematocrit at Month 6
Blood samples were collected for the measurement of hematocrit values. Change from Baseline was calculated as the Month 6 value minuse the Baseline value.
Time frame: Baseline and Month 6
Change From Baseline in Mean Corpuscle Hemoglobin at Month 6
Blood samples were collected for the measurement of hemoglobin values. Change from Baseline was calculated as the Month 6 value minus the Baseline value.
Time frame: Baseline and Month 6
Change From Baseline in Mean Corpuscular Volume at Month 6
Blood samples were collected for the measurement of mean corpuscular volume values. Change from Baseline was calculated as the Month 6 value minus the Baseline value.
Time frame: Baseline and Month 6
Change From Baseline in Red Blood Cell Count at Month 6
Blood samples were collected for the measurement of red blood cell count values. Change from Baseline was calculated as the Month 6 value minus the Baseline value.
Time frame: Baseline and Month 6
Change From Baseline in Red Cell Distribution Width at Month 6
Blood samples were collected for the measurement of red cell distribution width values. Change from Baseline was calculated as the Month 6 value minus the Baseline value.
Time frame: Baseline and Month 6
Number of Participants With Positive and Negative Results for Anti-body Formation to Denosumab at Month 6
The number of participants with positive and negative results for both neutralizing antibodies to denosumab and for binding antibodies to denosumab at Month 6 are summarized.
Time frame: Month 6
| Milestone | Denosumab 60 mg | Placebo |
|---|---|---|
| Started | 124 | 126 |
| Completed | 111 | 114 |
| Not completed | 13 | 12 |
| Withdrew: Lost to follow-up | 2 | 2 |
| Withdrew: Protocol violation | 1 | 0 |
| Withdrew: Withdrawal by subject | 10 | 10 |
Bone mineral density (BMD) at the lumbar spine was measured by the dual-energy x-ray absorptiometry (DXA) scanner. The mean percent change from Baseline in BMD was calculated as: (value at Month 6 minus Baseline value) \* 100 / Baseline value. Analysis was performed using an Analysis of Covariance (ANCOVA) model with terms for treatment and baseline BMD at the lumbar spine (as a continuous covariate).
| percent change | Denosumab 60 mg | Placebo |
|---|---|---|
| Mean Percent Change From Baseline in Bone Mineral Density at the Lumbar Spine at Month 6 | 4.26 ± 0.413 | 1.20 ± 0.403 |
BMD at the total hip, femoral neck, and trochanter was measured by the DXA scanner. The mean percent change from Baseline in BMD was calculated as: (value at Month 6 minus Baseline value) \* 100 / Baseline value. Analysis was performed using an ANCOVA model with terms for treatment and corresponding Baseline BMD (as a continuous covariate).
| percent change | Denosumab 60 mg | Placebo |
|---|---|---|
| Total Hip | 2.02 ± 0.270 | 0.32 ± 0.271 |
| Femoral Neck | 2.69 ± 0.407 | 0.40 ± 0.409 |
| Trochanter | 2.49 ± 0.366 | 0.69 ± 0.368 |
Blood samples were collected for the measurement of s-CTx and s-PINP, which are used as biomarkers of bone resorption and formation, respectively. The median percent change from Baseline in s-CTX and s-PINP markers at Months 1, 3, and 6 was calculated as: (post-Baseline value minus Baseline value) \* 100 / Baseline value.
| percent change | Denosumab 60 mg | Placebo |
|---|---|---|
| s-CTx, Month 1, n=112, 121 | -80.61 (-87.42 to -65.04) | -17.01 (-40.03 to 6.93) |
| s-CTx, Month 3, n=107, 113 | -82.43 (-87.50 to -66.54) | -18.97 (-44.25 to 3.56) |
| s-CTx, Month 6, n=105, 113 | -62.5 (-77.60 to -42.86) | -28.82 (-47.33 to -1.15) |
| s-PINP, Month 1, n=110, 120 | -34.55 (-50.00 to -21.74) | -13.62 (-23.94 to -2.21) |
| s-PINP, Month 3, n=107, 111 | -78.08 (-84.13 to -65.38) | -27.87 (-42.68 to -1.75) |
| s-PINP, Month 6, n=104, 113 | -63.41 (-76.50 to -53.85) | -25.81 (-41.79 to 0.00) |
An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, or is an event of possible drug-induced liver injury with hyperbilirubinaemia. Medical or scientific judgment was to have been exercised in other important medical events. Refer to the general Adverse AE/SAE module for a complete list of AEs and SAEs.
| participants | Denosumab 60 mg | Placebo |
|---|---|---|
| Any AE | 38 | 47 |
| Any SAE | 1 | 3 |
Vital sign values of potential clinical concern were defined as: change in heart rate \>30 beats per minutes (bpm), change in systolic blood pressure (SBP) \>30 millimeters of mercury (mmHg), and change in diastolic blood pressure (DBP) \>20 mmHg. The number of participants with post-Baseline vital sign values of potential clinical concern who did not have values of potential clinical concern at Baseline are summarized. If the change from Baseline is a decrease greater than the threshold, it is categorized as "low." If the change from Baseline is an increase greater than the threshold, it is categorized ad "high."
| participants | Denosumab 60 mg | Placebo |
|---|---|---|
| DBP, Month 1: High, n=122, 125 | 1 | 2 |
| DBP, Month 1: Low, n=122, 125 | 1 | 4 |
| DBP, Month 3: High, n=117, 120 | 2 | 0 |
| DBP, Month 3: Low, n=117, 120 | 0 | 2 |
| DBP, Month 6: Low, n=111, 114 | 0 | 3 |
| SBP, Month 1: Low, n=122, 125 | 1 | 2 |
| SBP, Month 3: High, n=117, 120 | 1 | 1 |
| SBP, Month 3: Low, n=117, 120 | 1 | 3 |
| SBP, Month 6: Low, n=111, 114 | 2 | 3 |
| Heart Rate, Month 3: Low, n=117, 120 | 0 | 1 |
The number of participants with laboratory parameter values of potential clinical concern at Month 6 are summarized. The following are the laboratory values of potential clinical concern: alkaline phosphatase, High: \>375 units/Liter (L); aspartate aminotransferase, High: \>165 units/L; creatinine, High: \>159 micromoles (µmol)/L; glucose, Low: \<3 millimoles (mmol)/L; hematocrit, Low: \<0.325; hemoglobin, Low: \<91grams/L; phosphorus, High: \>1.723 mmol/L; potassium, High: \>6.3 mmol/L; sodium, Low: \<130 mmol/L; total neutrophils, Low: \<0.9 10\^9 cells (GI)/L; blood urea nitrogen (BUN), High: \>21mmol/L; uric acid, High: 654 µmol/L.
| participants | Denosumab 60 mg | Placebo |
|---|---|---|
| Alkaline phosphatase: High, n=107, 114 | 0 | 1 |
| Aspartate aminotransferase: High, n=107, 113 | 1 | 0 |
| Creatinine: High, n=107, 114 | 1 | 1 |
| Glucose: Low, n=107, 114 | 1 | 0 |
| Hematocrit: Low, n=106, 111 | 1 | 1 |
| Hemoglobin: Low, n=106, 111 | 2 | 3 |
| Inorganic Phosphorus: High, n=107, 114 | 0 | 1 |
| Potassium: High, n=107, 113 | 1 | 0 |
| Sodium: Low, n=107, 114 | 0 | 1 |
| Total Neutrophils: Low, n=104, 107 | 0 | 2 |
| Urea/BUN: High, n=107, 114 | 0 | 1 |
| Uric Acid: High, n=107, 114 | 0 | 1 |
Blood samples were collected for the measurement of albumin/globulin ratio and BUN/creatinine ratio values. Change from Baseline was calculated as the Month 6 value minus the Baseline value.
| ratio | Denosumab 60 mg | Placebo |
|---|---|---|
| Albumin/globulin ratio | 0.025 ± 0.1446 | 0.018 ± 0.1518 |
| BUN/creatinine ratio | -5.896 ± 18.0195 | -1.860 ± 19.8400 |
Blood samples were collected for the measurement of albumin, hemoglobin, mean corpuscle hemoglobin concentration, and total protein values. Change from Baseline was calculated as the Month 6 value minus the Baseline value.
| grams per liter (g/L) | Denosumab 60 mg | Placebo |
|---|---|---|
| Albumin, n=106, 114 | 0.689 ± 2.4470 | 0.746 ± 2.9020 |
| Hemoglobin, n=106, 107 | 2.236 ± 6.2891 | 1.925 ± 8.4927 |
| Mean corpuscle hemoglobin conc., n=106, 107 | 2.321 ± 9.8653 | 1.607 ± 10.0196 |
| Total protein, n=106, 114 | 0.585 ± 3.8219 | 0.886 ± 4.1621 |
Blood samples were collected for the measurement of alkaline phosphatase, alanine amino transferase, aspartate amino transferase, creatinine kinase, gamma glutamyl transferase, and lactate dehydrogenase values. Change from Baseline was calculated as the Month 6 value minus the Baseline value.
| International units per liter (IU/L) | Denosumab 60 mg | Placebo |
|---|---|---|
| Alkaline phosphatase, n=106, 114 | -18.179 ± 25.0207 | -3.684 ± 41.4420 |
| Alanine amino transferase, n=106, 114 | 2.481 ± 10.2421 | 0.035 ± 15.6640 |
| Aspartate amino transferase, 106, 113 | 2.755 ± 10.9465 | -0.965 ± 16.9226 |
| Creatinine kinase, n=106, 114 | 6.170 ± 51.2968 | 11.175 ± 63.0331 |
| Gamma glutamyl transferase, n=106, 114 | 2.915 ± 12.8346 | -0.754 ± 13.8433 |
| Lactate dehydrogenase, n=106, 113 | 2.764 ± 25.2811 | 0.434 ± 36.7389 |
Blood samples were collected for the measurement of basophil, eosinophil, lymphocyte, monocyte, segmented neutrophil, total neutrophil, platelet count, and white blood cell count values. Change from Baseline was calculated as the Month 6 value minus the Baseline value.
| 10^9 cells per liter (GI/L) | Denosumab 60 mg | Placebo |
|---|---|---|
| Basophils, n=104, 103 | 0.001 ± 0.0221 | -0.001 ± 0.0262 |
| Eosinophils, n=104, 103 | -0.076 ± 0.2794 | -0.001 ± 0.3414 |
| Lymphocytes, n=104, 103 | -0.065 ± 0.6044 | -0.056 ± 0.7476 |
| Monocytes, n=104, 103 | 0.000 ± 0.1204 | 0.032 ± 0.1727 |
| Segmented neutrophils, n=104, 103 | -0.290 ± 1.6142 | -0.129 ± 1.7405 |
| Total neutrophils, n=104, 103 | -0.297 ± 1.6099 | -0.135 ± 1.7343 |
| Platelet count, n=103, 105 | 3.117 ± 38.5322 | 7.533 ± 36.5761 |
| White blood cell count, n=104, 103 | -0.436 ± 1.6614 | -0.160 ± 1.7629 |
Blood samples were collected for the measurement of direct bilirubin, indirect bilirubin, total bilirubin, creatinine, and uric acid values. Change from Baseline was calculated as the Month 6 value minus the Baseline value.
| micromoles per liter (UMOL/L) | Denosumab 60 mg | Placebo |
|---|---|---|
| Direct bilirubin, n=105, 112 | 0.152 ± 1.1667 | 0.089 ± 1.2122 |
| Indirect bilirubin, n=105, 112 | 0.210 ± 2.7305 | -0.054 ± 2.2050 |
| Total bilirubin, n=106, 114 | 0.358 ± 2.8659 | 0.000 ± 2.2102 |
| Creatinine, n=106, 114 | 2.337 ± 11.8458 | 3.041 ± 13.1471 |
| Uric acid, n=106, 114 | -2.642 ± 60.6677 | -6.316 ± 61.9058 |
Blood samples were collected for the measurement of calcium corrected, calcium, chloride, glucose, potassium, magnesium, sodium, phosphorus inorganic, triglyceride, urea/BUN, and VLDL cholesterol calculation values. Change from Baseline was calcualted as the Month 6 value minus the Baseline value.
| millimoles per liter (MMOL/L) | Denosumab 60 mg | Placebo |
|---|---|---|
| Calcium corrected, n=12, 24 | 0.015 ± 0.0573 | 0.008 ± 0.0755 |
| Calcium, n=106, 113 | 0.012 ± 0.1194 | 0.033 ± 0.1069 |
| Chloride, n=106, 114 | -0.802 ± 3.0376 | -0.895 ± 3.0552 |
| Glucose, n=106, 113 | -0.571 ± 2.2401 | -0.303 ± 2.6346 |
| Potassium, n=106, 113 | 0.140 ± 0.4581 | 0.158 ± 0.4118 |
| Magnesium, n=106, 114 | 0.009 ± 0.0718 | 0.009 ± 0.0614 |
| Sodium, n=106, 114 | -0.472 ± 2.2979 | -0.395 ± 2.5921 |
| Phosphorus inorganic, n=106, 114 | -0.052 ± 0.2047 | -0.012 ± 0.1674 |
| Triglycerides, n=106, 114 | -0.305 ± 0.7413 | -0.263 ± 0.8433 |
| Urea/BUN, n=106, 114 | -0.283 ± 1.1423 | 0.114 ± 2.2032 |
| VLDL cholesterol calculation, n=103, 109 | -0.131 ± 0.3178 | -0.105 ± 0.3504 |
Blood samples were collected for the measurement of hematocrit values. Change from Baseline was calculated as the Month 6 value minuse the Baseline value.
| proportion of RBCs in blood | Denosumab 60 mg | Placebo |
|---|---|---|
| Change From Baseline in Hematocrit at Month 6 | 0.004 ± 0.0204 | 0.004 ± 0.0264 |
Blood samples were collected for the measurement of hemoglobin values. Change from Baseline was calculated as the Month 6 value minus the Baseline value.
| picograms | Denosumab 60 mg | Placebo |
|---|---|---|
| Change From Baseline in Mean Corpuscle Hemoglobin at Month 6 | 0.407 ± 0.8613 | 0.260 ± 1.2787 |
Blood samples were collected for the measurement of mean corpuscular volume values. Change from Baseline was calculated as the Month 6 value minus the Baseline value.
| femtoliters | Denosumab 60 mg | Placebo |
|---|---|---|
| Change From Baseline in Mean Corpuscular Volume at Month 6 | 0.623 ± 2.9775 | 0.327 ± 3.5309 |
Blood samples were collected for the measurement of red blood cell count values. Change from Baseline was calculated as the Month 6 value minus the Baseline value.
| 10^12 cells per liter (TI/L) | Denosumab 60 mg | Placebo |
|---|---|---|
| Change From Baseline in Red Blood Cell Count at Month 6 | 0.016 ± 0.2575 | 0.034 ± 0.3034 |
Blood samples were collected for the measurement of red cell distribution width values. Change from Baseline was calculated as the Month 6 value minus the Baseline value.
| percentage | Denosumab 60 mg | Placebo |
|---|---|---|
| Change From Baseline in Red Cell Distribution Width at Month 6 | 0.065 ± 1.2126 | -0.121 ± 1.2735 |
The number of participants with positive and negative results for both neutralizing antibodies to denosumab and for binding antibodies to denosumab at Month 6 are summarized.
| participants | Denosumab 60 mg | Placebo |
|---|---|---|
| Neutralizing antibodies, n=0, 0 | NA | NA |
| Binding antibodies, Positive, n=110, 114 | 0 | 0 |
| Binding antibodies, Negative, n=110, 114 | 110 | 114 |
Collected over SAEs (serious adverse events) and non-serious AEs were collected from the start of study medication through the study period (6-month post-dose) (up to Study Week 43).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Denosumab 60 mg | — | 1/124 (0.8%) | 8/124 (6.5%) |
| Placebo | — | 3/126 (2.4%) | 3/126 (2.4%) |
| Event | Denosumab 60 mg | Placebo |
|---|---|---|
| Cataract nuclearEye disorders | 1/124 | 0/126 |
| HypotensionVascular disorders | 0/124 | 1/126 |
| Varicose vein rupturedVascular disorders | 0/124 | 1/126 |
| AstheniaGeneral disorders | 0/124 | 1/126 |
| Liver abscessInfections and infestations | 0/124 | 1/126 |
| Hepatic enzyme increasedInvestigations | 0/124 | 1/126 |
| Event | Denosumab 60 mg | Placebo |
|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 8/124 | 3/126 |
| Age, Continuous(Years) | Denosumab 60 mg | Placebo | Total |
|---|---|---|---|
| Mean | 62.6 ± 5.10 | 62.6 ± 4.85 | 62.6 ± 4.96 |
| Sex: Female, Male(Participants) | Denosumab 60 mg | Placebo | Total |
|---|---|---|---|
| Female | 124 | 126 | 250 |
| Male | 0 | 0 | 0 |
| Race/Ethnicity, Customized(participants) | Denosumab 60 mg | Placebo | Total |
|---|---|---|---|
| Asian - Central/South Asian Heritage | 124 | 126 | 250 |
The record gives a start of Jan 2012, a primary completion of Feb 2013 and a completion of Feb 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2013, 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Denosumab
Osteoporosis, Postmenopausal →